Gain Therapeutics, Inc.
GANXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Gain Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Gain Therapeutics, Inc. — 10-K filed Mar 27, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Mar 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 11,050 | Not shown | SEC filing |
| Cresset Asset Management, LLC | 2026-03-31 | 160,000 | Not shown | SEC filing |
| Virtu Financial LLC | 2026-03-31 | 10,685 | Not shown | SEC filing |
| LPL Financial LLC | 2026-03-31 | 104,251 | Not shown | SEC filing |
| Millington Financial Advisors, LLC | 2026-03-31 | 15,000 | Not shown | SEC filing |
| BlackRock, Inc. | 2026-03-31 | 225,046 | Not shown | SEC filing |
| JANE STREET GROUP, LLC | 2026-03-31 | 216,883 | Not shown | SEC filing |
| Schonfeld Strategic Advisors LLC | 2026-03-31 | 24,500 | Not shown | SEC filing |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 2026-03-31 | 15,556 | Not shown | SEC filing |
| BENEDICT FINANCIAL ADVISORS INC | 2026-03-31 | 15,500 | Not shown | SEC filing |
| DME Capital Management, LP | 2026-03-31 | 566,130 | Not shown | SEC filing |
| CITIGROUP INC | 2026-03-31 | 1 | Not shown | SEC filing |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2026-03-31 | 431,267 | Not shown | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 13,439 | Not shown | SEC filing |
| PRELUDE CAPITAL MANAGEMENT, LLC | 2026-03-31 | 35,820 | Not shown | SEC filing |
| JONES FINANCIAL COMPANIES LLLP | 2026-03-31 | 631,615 | Not shown | SEC filing |
| UBS Group AG | 2026-03-31 | 220,489 | Not shown | SEC filing |
| COMMONWEALTH EQUITY SERVICES, LLC | 2026-03-31 | 29,703 | Not shown | SEC filing |
| MORGAN STANLEY | 2026-03-31 | 139,652 | Not shown | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 1,700 | Not shown | SEC filing |
- Each value is checked against Gain Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 20 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- Apollon Wealth Management, LLC: 19,825 shares reported 2025-12-31; 26,500 shares reported 2026-03-31.
- CITADEL ADVISORS LLC: 373,558 shares reported 2025-09-30; 24,900 shares reported 2026-03-31.
- Tower Research Capital LLC (TRC): 6,859 shares reported 2025-12-31; 5,506 shares reported 2026-03-31.
- Potomac Capital Management, Inc.: 1,010,000 shares reported 2025-12-31; 1,008,600 shares reported 2026-03-31.
- Larson Financial Group LLC: 10 shares reported 2025-12-31; 10 shares reported 2026-03-31.
- Sandhill Capital Partners LLC: 15,400 shares reported 2025-12-31; 15,400 shares reported 2026-03-31.
- NewEdge Advisors, LLC: 10,600 shares reported 2025-12-31; 10,600 shares reported 2026-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 397,942 shares reported 2025-12-31; 447,342 shares reported 2026-03-31.
- BRIDGEWAY CAPITAL MANAGEMENT, LLC: 30,004 shares reported 2025-12-31; 30,004 shares reported 2026-03-31.
- Cambridge Investment Research Advisors, Inc.: 568,645 shares reported 2025-12-31; 568,645 shares reported 2026-03-31.
- GSA CAPITAL PARTNERS LLP: 20,472 shares reported 2025-12-31; 312,467 shares reported 2026-03-31.
- Kestra Advisory Services, LLC: 12,000 shares reported 2025-12-31; 12,000 shares reported 2026-03-31.
Showing the 12 most recent filer reports.
23 filers have only one report here.
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2024-08-09 | Mack Gene · CFO and Interim CEO | Common Stock | P — Open market or private purchase | +14,400 | 1.01 | SEC filing |
| 2024-08-09 | Islam Khalid · Executive Chairman | Common Stock | P — Open market or private purchase | +50,000 | 1.00 | SEC filing |
| 2024-07-01 | RICHMAN ERIC I · Director | Common Stock | P — Open market or private purchase | +5,000 | 1.23 | SEC filing |
| 2024-07-01 | RICHMAN ERIC I · Director | Common Stock | P — Open market or private purchase | +12,000 | 1.21 | SEC filing |
| 2024-03-28 | Riley Jeffrey Scott · Director | Common Stock | P — Open market or private purchase | +30,000 | 3.86 | SEC filing |
| 2023-12-21 | Alder Matthias · Chief Executive Officer | Common Stock | S — Open market or private sale | −206 | 2.46 | SEC filing |
| 2023-12-07 | Alder Matthias · Chief Executive Officer | Common Stock | S — Open market or private sale | −1,820 | 2.50 | SEC filing |
| 2022-05-25 | RICHMAN ERIC I · CHIEF EXECUTIVE OFFICER | Common stock | P — Open market or private purchase | +2,482 | 2.58 | SEC filing |
Showing 8 of 12 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-03-24 | Fuggetta Gianluca · See Remark | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +50,000 | SEC filing |
| 2026-03-24 | Mack Gene · CEO, President | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +200,000 | SEC filing |
| 2025-06-24 | HASLER HANS PETER · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-06-24 | Islam Khalid · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-06-24 | GOLDSTEIN DOV A MD · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-06-24 | Melincoff Gwen A · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-06-24 | Riley Jeffrey Scott · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
| 2025-06-24 | RICHMAN ERIC I · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +15,000 | SEC filing |
Showing 8 of 21 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.